BMO Maintains Outperform on Pfizer (PFE) March 2026

NodeGuardian · 2026-03-10T06:22:05+00:00

BMO Capital maintains its Outperform rating on Pfizer after Phase 2 data, reflecting confidence in its pipeline. The market responded with a minor 0.77% increase, indicating expectations were already met.

NodeGuardian

2026-03-10 06:22:05

Abstract generation in progress

BMO Capital has reiterated its Outperform rating on Pfizer Inc. (PFE) following the release of Phase 2 data, a decision that maintains confidence in the company’s development pipeline. This action is a reaffirmation rather than an upgrade or downgrade, as no new price target was published. The market’s immediate response was a modest 0.77% increase, indicating that the Phase 2 results were largely anticipated.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes